Last updated: September 8, 2026
Vaxelis is a U.S.-licensed hexavalent pediatric vaccine developed through the Sanofi and Merck partnership. Its commercial position depends on public-sector procurement, pediatric combination-vaccine adoption, manufacturing reliability, and competition from Pediarix and Pentacel. Standalone Vaxelis revenue is not publicly disclosed by either company, so financial analysis relies on regulatory milestones, market access, portfolio disclosures, and vaccine procurement dynamics rather than reported product sales.
What is Vaxelis and which market does it serve?
Vaxelis is a six-component combination vaccine for infants and young children. It covers diphtheria, tetanus, pertussis, poliovirus, Haemophilus influenzae type b, and hepatitis B.
| Attribute |
Vaxelis profile |
| Active components |
DTaP-IPV-Hib-HepB |
| U.S. trade name |
Vaxelis |
| U.S. biologic license holder |
MCM Vaccine B.V. |
| Commercial partners |
Merck and Sanofi |
| FDA approval |
December 2018 |
| U.S. indication |
Three-dose primary series at 2, 4, and 6 months |
| Administration |
Intramuscular injection |
| Market |
Infant and pediatric combination vaccines |
| Product category |
Preventive biologic vaccine |
| Main U.S. alternatives |
Pediarix and Pentacel |
| Primary procurement channels |
Private pediatric practices, health systems, and the Vaccines for Children program |
The product reduces the number of injections required during the infant immunization schedule. Its principal commercial value is operational: providers can administer one combination product instead of separate vaccines while maintaining coverage for six diseases.
The FDA approved Vaxelis under a biologics license application. The product is not a conventional small-molecule drug and does not compete through the standard abbreviated new drug application pathway used for generic medicines.[1]
When did Vaxelis launch and how has adoption developed?
Vaxelis entered the U.S. market after FDA approval in 2018, with commercial availability following launch preparations by Merck and Sanofi. Uptake was initially shaped by the need to obtain recommendations, establish reimbursement, secure provider familiarity, and qualify for public procurement.
The product gained commercial relevance after inclusion in U.S. pediatric immunization procurement programs. The Vaccines for Children program is particularly important because it purchases vaccines for eligible children and distributes them through participating providers. Public-sector contracts can generate volume but typically place greater pressure on price and supply reliability than private-sector sales.
Vaxelis regulatory timeline
| Date |
Event |
| December 2018 |
FDA approved Vaxelis for the three-dose infant primary series |
| 2019-2020 |
Commercial launch and provider-market development |
| 2021 onward |
Expanded presence in U.S. public and private pediatric procurement |
| 2023-2025 |
Continued competition with established combination vaccines and broader vaccine-supply normalization |
CDC guidance identifies Vaxelis as one of the products that can be used in the infant primary series. Interchangeability and dose-history considerations remain important because pediatric providers may use different products across visits depending on inventory and prior vaccination.[2]
How large is the U.S. pediatric combination-vaccine market?
The U.S. market is concentrated among a small number of suppliers. Pediatric vaccination demand is relatively predictable because it is tied to birth cohorts and national immunization schedules, but product selection varies by contract, state, provider system, and payer.
The key demand drivers are:
- Annual U.S. birth volume.
- CDC and state purchasing contracts.
- Pediatrician preference for fewer injections.
- Availability of combination products.
- Reimbursement and administration economics.
- Supply continuity during manufacturing interruptions.
- Changes in the recommended immunization schedule.
- Provider efforts to reduce missed or delayed vaccinations.
The market is less exposed to direct consumer advertising than many pharmaceutical categories. Clinical guideline inclusion, procurement pricing, supply performance, and provider education have greater commercial impact.
How does Vaxelis compare with Pediarix and Pentacel?
| Product |
Manufacturer |
Covered diseases |
Typical role |
| Vaxelis |
Sanofi/Merck partnership |
Six |
Three-dose infant primary series |
| Pediarix |
GSK |
Five |
DTaP-IPV-HepB combination, generally used for the primary infant series |
| Pentacel |
Sanofi |
Five |
DTaP-IPV-Hib combination |
| Separate vaccines |
Multiple suppliers |
Varies |
Used when combination products are unavailable or clinically unsuitable |
Vaxelis has a broader antigen profile than Pediarix and Pentacel because it includes Hib while also including hepatitis B. That can reduce the number of products required for the primary series. The tradeoff is greater manufacturing complexity and dependence on a tightly controlled combination-product supply chain.
Pediarix has established provider familiarity and a long commercial history. Pentacel has a strong position in the DTaP-IPV-Hib segment. Vaxelis competes by combining six antigens, supporting supply diversification, and leveraging the commercial reach of both Sanofi and Merck.
What is the financial trajectory of Vaxelis?
Vaxelis revenue is not separately reported in the public financial statements of Merck or Sanofi. Both companies disclose vaccine sales at broader portfolio or business-unit levels. This prevents a precise public calculation of Vaxelis sales, gross margin, market share, or product-level growth rate.
Financial indicators that can be assessed
| Indicator |
Public visibility |
Commercial implication |
| Standalone Vaxelis revenue |
Not separately disclosed |
Product-level sales cannot be independently verified from company filings |
| Vaccine segment revenue |
Disclosed by Merck and Sanofi |
Shows broader portfolio performance, not Vaxelis-specific growth |
| U.S. contract participation |
Publicly observable through CDC and government procurement sources |
Indicates access to volume-based demand |
| FDA status |
Public |
Supports continued commercial supply |
| Product pricing |
Varies by purchaser and channel |
Public-sector pricing may differ materially from private-sector pricing |
| Manufacturing network |
Partially disclosed |
Supply resilience affects sales continuity and contract performance |
| Competitor availability |
Publicly observable |
Creates switching and pricing pressure |
Merck’s vaccine business is dominated by larger products, particularly Gardasil and related franchises. Sanofi’s vaccine business includes influenza, respiratory, meningococcal, travel, and pediatric products. Vaxelis is therefore strategically relevant but unlikely to be a primary driver of either company’s consolidated revenue.
The most likely financial profile is a stable, volume-oriented pediatric vaccine product rather than a high-price specialty biologic. Revenue growth depends more on units administered and procurement wins than on price increases. Margin performance is affected by antigen manufacturing costs, fill-finish capacity, cold-chain logistics, quality-control expenses, and contract pricing.
What patents protect Vaxelis and when does exclusivity end?
Vaxelis does not have the same public patent-transparency profile as a traditional small-molecule drug. The FDA Orange Book primarily lists approved drug products and patent information submitted for those products. Vaxelis is a biologic vaccine licensed under a biologics license application, and it is not generally analyzed as an Orange Book-listed product with a conventional small-molecule patent-expiration date.[3]
Protection may instead arise from:
- Manufacturing know-how.
- Antigen production processes.
- Purification and conjugation methods.
- Stabilization and formulation technology.
- Combination-composition claims.
- Container and delivery systems.
- Trade secrets.
- Regulatory exclusivity.
- Contractual and manufacturing barriers.
A single, publicly established “Vaxelis patent expiration date” should not be treated as the product’s effective loss-of-exclusivity date. The enforceable position depends on the specific patent family, jurisdiction, claim scope, maintenance status, and whether a potential competitor can design around the claims.
Does Vaxelis have a biosimilar or interchangeable competitor?
No biosimilar or interchangeable competitor is publicly established for Vaxelis in the United States. The product’s complexity makes direct replication difficult. A competing manufacturer would need to address the full antigen combination, analytical comparability, clinical and manufacturing requirements, and FDA licensure.
The absence of a biosimilar does not eliminate competition. Another manufacturer can develop a separately licensed combination vaccine or use existing vaccines in a different product configuration. That route is commercially and technically demanding but does not depend on the traditional biosimilar pathway.
What is the FDA and Orange Book status of Vaxelis?
Vaxelis is FDA-approved as a biologic vaccine. Its regulatory framework is the Public Health Service Act biologics pathway rather than the standard small-molecule generic pathway.
The FDA label describes the product as a three-dose series administered at 2, 4, and 6 months. Vaxelis is not intended to replace all possible pediatric vaccination schedules, and providers must follow product-specific age, dose, and prior-vaccination instructions.[1]
The Orange Book is not the principal source for Vaxelis exclusivity analysis. Analysts should instead review:
- FDA biologics license records.
- FDA prescribing information.
- CDC immunization schedules.
- CDC Vaccine Price Lists and contract materials.
- USPTO patent records.
- Patent assignment and maintenance data.
- Company regulatory and annual reports.
What generic entry risks exist for Vaxelis?
Traditional generic-entry risk is low because Vaxelis is a biologic combination vaccine with no standard ANDA substitution route. The more relevant risks are competitive-entry and supply-substitution risks.
Competitive risks
- A rival six-component vaccine could capture contracts or provider share.
- Pediarix and Pentacel can remain substitutes within the pediatric schedule.
- Separate vaccine administration can replace Vaxelis when inventory or clinical history requires it.
- Government buyers can shift volume among qualified suppliers.
- Manufacturing interruptions can move providers toward available alternatives.
Regulatory and manufacturing barriers
A new competitor would need validated production for multiple antigens, consistent potency and purity, reliable conjugation or combination processes, extensive quality controls, and sufficient capacity to support national demand. The Hib and pertussis components add technical complexity, while supply continuity requires multiple specialized production steps.
Manufacturing know-how may be more important than publicly visible patent count. A competitor with patents but no qualified commercial-scale capacity would not pose immediate launch risk.
What patent litigation and Paragraph IV challenges affect Vaxelis?
No major publicly established Paragraph IV litigation campaign is associated with Vaxelis. Paragraph IV litigation is an ANDA mechanism for challenging patents listed in the Orange Book. Because Vaxelis is a biologic vaccine and is not generally treated as an Orange Book small-molecule product, a conventional Paragraph IV launch challenge is not the expected route.
Potential disputes would more likely involve:
- Patent infringement claims against a separately licensed competing vaccine.
- Trade-secret or manufacturing-process disputes.
- Contract and supply agreements.
- Regulatory exclusivity or licensure issues.
- Product liability and quality claims.
There is no established settlement agreement publicly defining an authorized generic or biosimilar launch date for Vaxelis.
Which companies are challenging Vaxelis commercially?
The principal commercial challengers are GSK through Pediarix and Sanofi’s own Pentacel franchise, although Sanofi and Merck jointly commercialize Vaxelis. This creates portfolio overlap within Sanofi: Vaxelis can gain volume in settings where Pentacel previously supplied much of the combination-vaccine demand.
Other competitive pressure comes from manufacturers of standalone DTaP, IPV, Hib, and hepatitis B vaccines. These products can substitute for Vaxelis when providers manage inventory, accommodate prior doses, or follow catch-up schedules.
The competitive environment is therefore concentrated but not static. The main contest is over contracts, provider preference, supply reliability, and product fit rather than direct retail price competition.
How strong is the Vaxelis commercial and intellectual-property position?
Vaxelis has a strong regulatory and manufacturing position but a less transparent patent position.
| Factor |
Assessment |
| FDA approval |
Strong |
| Clinical schedule fit |
Strong for the infant primary series |
| Combination convenience |
Strong |
| Public-sector access |
Important and potentially strong |
| Brand recognition |
Moderate relative to established alternatives |
| Standalone revenue transparency |
Limited |
| Generic substitution risk |
Low |
| Product-specific patent transparency |
Limited |
| Manufacturing complexity |
High barrier to entry |
| Pricing power |
Moderate to limited in public procurement |
| Competitive durability |
Dependent on contracts and supply performance |
The product’s effective moat is based on regulatory approval, quality systems, manufacturing scale, and market access. Patent rights may support that position, but publicly visible patent expiration alone does not define the competitive timeline.
What is the outlook for Vaxelis revenue?
Vaxelis should be viewed as a durable pediatric vaccine franchise with moderate growth potential and limited product-level disclosure. Revenue should track:
- U.S. birth cohorts.
- Vaxelis share of the three-dose infant series.
- CDC and state contract awards.
- Private-practice adoption.
- Product availability.
- Competitor shortages or manufacturing interruptions.
- Changes in the pediatric immunization schedule.
Upside would come from higher penetration of combination vaccination, additional procurement wins, and sustained supply performance. Downside would come from contract losses, manufacturing disruption, provider switching, or reduced use of combination products.
The product is unlikely to produce the financial profile of a specialty biologic with premium pricing. Its value is more consistent with a strategic vaccine franchise that generates recurring volume and strengthens the partners’ positions in pediatric immunization.
Key Takeaways
- Vaxelis is a six-component pediatric biologic vaccine marketed through a Sanofi-Merck partnership.
- FDA approval occurred in December 2018 for the infant three-dose primary series.
- Its principal U.S. competitors are Pediarix and Pentacel.
- Standalone Vaxelis revenue is not publicly disclosed.
- The product’s economics depend on procurement contracts, birth cohorts, provider adoption, and supply reliability.
- Vaxelis is not best analyzed through a conventional Orange Book or Paragraph IV framework.
- No biosimilar or interchangeable competitor is publicly established.
- Manufacturing complexity, regulatory approval, quality systems, and supply capacity are material barriers to entry.
- The product has a stronger commercial and manufacturing moat than a transparent, easily quantifiable patent moat.
- The most credible financial outlook is recurring, volume-based pediatric vaccine revenue with moderate pricing power.
FAQs
Is Vaxelis a live vaccine?
No. Vaxelis is a non-live combination vaccine composed of toxoids, inactivated poliovirus, recombinant hepatitis B antigen, and conjugated Hib antigen.
Can Vaxelis be used for catch-up vaccination?
Use depends on the child’s age, prior doses, product history, and current CDC recommendations. Vaxelis is primarily positioned for the infant primary series and is not a universal replacement for every catch-up schedule.
Who manufactures Vaxelis?
Vaxelis is associated with MCM Vaccine B.V., a Sanofi-Merck partnership. Manufacturing and distribution responsibilities are allocated through the partnership and its operating entities.
Is Vaxelis interchangeable with Pediarix?
Vaxelis and Pediarix do not have identical antigen compositions. Product substitution must follow CDC guidance, FDA labeling, and the child’s vaccination history.
Does Vaxelis have a patent cliff?
Vaxelis does not have a single publicly established patent-cliff date comparable to a conventional small-molecule drug. Competitive exposure is more likely to develop through separately licensed combination vaccines, procurement competition, and manufacturing capabilities.
References
- U.S. Food and Drug Administration. (2018). Vaxelis prescribing information. https://www.fda.gov
- Centers for Disease Control and Prevention. (2024). Child and adolescent immunization schedule by age. https://www.cdc.gov/vaccines/schedules
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/
- Merck & Co., Inc. (2024). Annual report. https://www.merck.com
- Sanofi. (2024). Universal registration document and annual financial report. https://www.sanofi.com
